Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial

ConclusionsIn this study we observed that in later-stage ADPKD, octreotide-LAR slowed kidney growth and delayed progression to ESRD, in particular in CKD stage 4. Trial registrationClinicalTrials.gov NCT01377246; EudraCT: 2011-000138-12.

http://feedproxy.google.com/~r/plosmedicine/NewArticles/~3/Rp2gwXsEpcM/article

Source: PLoS Medicine - April 4, 2019 Category: Internal Medicine Authors: Norberto Perico Source Type: research